Standardized response criteria to interpret and compare clinical trials are needed for
approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet …

European experts were convened to develop a definition of response to treatment in
polycythemia vera (PV) and essential thrombocythemia (ET). Clinicohematologic (CH) …

Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia
(ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong …

Criteria of response and definition of resistance and intolerance to hydroxyurea (HU) in
polycythemia vera (PV) were proposed by the European LeukemiaNet (ELN). Such criteria …

Major causes of morbidity and mortality in polycythemia vera (PV) and essential
thrombocythemia (ET) are represented by thrombosis and bleeding, progression to …

Abstract Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

A definition of response by cytoreductive therapy in essential thrombocythemia was recently
provided by the European LeukemiaNet (ELN). Complete, partial, or no clinicohematologic …

Because the current therapy in polycythemia vera (PV) and essential thrombocythemia (ET)
is aimed at lowering the risk of thrombosis, the risk classification system in these disorders is …

Recently reported mature survival data have confirmed the favorable prognosis in
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …

The Polycythemia Vera Study Group (PVSG) was organized in 1967 to identify the optimal
approach to the diagnosis and treatment of polycythemia vera (PV). Nevertheless, a …